2022

1. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

   Journal of Clinical Medicine, Vol. 11, Núm. 2

2. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

   Cancer, Vol. 128, Núm. 13, pp. 2441-2448

3. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

   Journal of Clinical Medicine, Vol. 11, Núm. 24

4. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

   Journal of Clinical Medicine, Vol. 11, Núm. 15